UNIT vs URGN Comparison

Uniti is the product of the August 2025 merger of the firm with Windstream, its former primary customer. The combined firm owns a 240,000 route-mile fiber network that serves enterprise and residential customers. Selling high-capacity fiber circuits to enterprises generates about 20% of consolidated revenue. Uniti's residential networks reach about 4.5 million households, mostly in less-populated markets in the Southeast, but only about 1.9 million of these locations have been upgraded with fiber. Legacy copper-cable networks serve the remainder. Residential services account for about a third of total revenue. Small business and wholesale services provided within this residential service territory account for about 20% of revenue.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.